Reuters logo
BRIEF-Mologen: positive subgroup results of exploratory phase II impulse study of lefitolimod in SCLC
April 24, 2017 / 5:29 AM / in 6 months

BRIEF-Mologen: positive subgroup results of exploratory phase II impulse study of lefitolimod in SCLC

April 24 (Reuters) - Mologen Ag:

* Positive subgroup results of the exploratory phase II IMPULSE study of lefitolimod in extensive-disease small-cell lung cancer (SCLC)

* Results are indicative for further development of lefitolimod in SCLC

* Randomized study evaluated efficacy and safety of lefitolimod in patients with extensive-disease small-cell lung cancer (SCLC) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below